vTv Therapeutics Q2 EPS $(0.07), Inline
Portfolio Pulse from Benzinga Newsdesk
vTv Therapeutics reported Q2 losses of $(0.07) per share, which met the analyst consensus estimate. This is a 75% decrease over losses of $(0.04) per share from the same period last year.
August 11, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
vTv Therapeutics reported Q2 losses in line with analyst estimates, but the losses increased by 75% compared to the same period last year.
While vTv Therapeutics met analyst estimates for Q2, the significant increase in losses compared to the same period last year could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100